Ernexa Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ERNA | XBIO | AIM | NCEL | IMNN | CELZ | |
|---|---|---|---|---|---|---|
| Market cap | 3.25M | 4.71M | 6.42M | 14.79M | 5.09M | 4.95M |
| P/E (TTM) | — | — | — | 4.9 | — | — |
| Forward P/E | -0.2 | -3.0 | -0.4 | -4.3 | -0.5 | -0.7 |
| Price/book | 0.7 | 0.8 | 0.6 | 2.3 | 2.2 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −95.10% | −26.10% | −90.12% | −38.31% | −77.02% | −78.05% |
| Today | −1.49% | −3.37% | +0.19% | −3.03% | +0.78% | −3.21% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ERNA news ›CRISPR Therapeutics (NASDAQ:CRSP) and Ernexa Therapeutics (NASDAQ:ERNA) Head to Head Review
Posted by Mitch Edgeman on Nov 3rd, 2026 Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…
Ernexa Therapeutics posts investor presentation under Regulation FD, available on investor site
TradingView Ernexa Therapeutics posts investor presentation under Regulation FD, available on investor site Ernexa Therapeutics made an investor presentation available under Regulation FD and posted it o
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
The Manila Times Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology un
Ernexa Therapeutics to present cell therapy progress in virtual investor event on Oct 15
Ernexa Therapeutics announced a virtual investor event on October 15, featuring its CEO and scientific leaders discussing the advancement of their lead cell therapy candidate, ERNA-101, aimed at treating advanced cancers like ovarian…
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk at Next-Generation Cancer Therapeutics Meeting for Preclinical Ovarian Cancer Data
Ernexa Therapeutics announced preclinical data for ERNA-101, highlighting its promise in ovarian cancer treatments, at a major conference. ERNA-101 is Ernexa’s lead cell therapy program aimed at treating advanced ovarian cancer by…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- quiverquant.com2
- stocktitan.net2
- globenewswire.com1
- manilatimes.net1
- pluang.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.